Paediatric Atypical Antipsychotic Monitoring Safety (PAMS) study: Pilot study in children and adolescents in secondary- and tertiary-care settings

Drug Safety

Volumn 32, Issue 4, 2009, Pages 325-333

  Rani, Fariz A ^a,b,c   Byrne, Patrick J ^d,e   Murray, MacEy L ^a,b   Carter, Paul ^f   Wong, Ian C K ^a,b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MALAYA   (Malaysia)

^d BETHLEM ROYAL HOSPITAL   (United Kingdom)

^e SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^f Walsall Community Health   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; BEHAVIOR DISORDER; CHILD; CLINICAL PRACTICE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; FECES INCONTINENCE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; PRESCRIPTION; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; TACHYCARDIA; WEIGHT GAIN;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CHILD; DRUG MONITORING; DRUG UTILIZATION; HUMANS; HYPERPROLACTINEMIA; PILOT PROJECTS; PROSPECTIVE STUDIES; WEIGHT GAIN;

EID: 65949109500     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200932040-00006     Document Type: Article

References (27)

1. Bramble D. Annotation: the use of psychotropic medications in children: a British view. J Child Psychol Psychiatry 2003; 44 (2): 169-79
2. Anderson L, Campbell M, Grega D, et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984; 141 (10): 1195-202
3. Naruse H, Nagahata M, Nakane Y, et al. A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiatry 1982; 48: 173-84
4. Frangou S, Byrne P. How to manage the first episode of schizophrenia. BMJ 2000; 321: 522-3
5. Malone R, Sheikh R, Zito J. Novel antipsychotic medications in the treatment of children and adolescents. Psychiatr Serv 1999; 50 (2): 171-4
6. Cheng-Shannon J, McGough J, Pataki C, et al. Secondgeneration antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2004; 14 (3): 372-94
7. Rani F, Murray ML, Byrne PB, et al. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 2008; 121 (5): 1002-9
8. Martin A, Leslie D. Trends in psychotropic medication costs for children and adolescents, 1997-2000. Arch Pediatr Adolesc Med 2003; 157 (10): 997-1004
9. Laita P, Cifuentes A, Doll A, et al. Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol 2007; 17 (4): 487-501
10. Vitiello B, Riddle MA, Greenhill LL, et al. How can we improve the assessment of safety in child and adolescent psychopharmacology? J Am Acad Child Adolesc Psychiatry 2003; 42 (6): 634-41
11. Hanft A, Eggleston CF, Bourgeois JA. Neuroleptic malignant syndrome in an adolescent after brief exposure to olanzapine. J Child Adolesc Psychopharmacol 2004; 14 (3): 481-7
12. Kumra S, Herion D, Jacobsen LK, et al. Case study: Risperidone induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 1997; 36 (5): 701-5
13. Royal College of Paediatrics and Child Health. Safer and better medicines for children: developing the clinical and research base of paediatric pharmacology in the United Kingdom. A review commissioned by the Medical Research Council, the Department of Health, and the Association of British Pharmaceutical Industry. May 2004 [online]. Available from URL: http://www.rcpch.ac.uk/Publications/Publications-list-by-date [Accessed 2008 Feb 7]
14. Choonara I. Paediatric pharmacovigilance. Paediatr Perinat Drug Ther 2006; 7 (2): 50-3
15. ICH harmonised tripartite guideline. Clinical safety data management: definitions and standards for expedited reporting 1994 [online]. Available from URL: http://www.ich.org/LOB/media/MEDIA436.pdf [Accessed 2008 Jan 3]
16. Greenhill LL, Vitiello B, Abikoff H, et al.Developing methodologies for monitoring long-term safety of psychotropic medications in children: report on the NIMH conference, September 25, 2000. J Am Acad Child Adolesc Psychiatry 2003; 42 (6): 651-5
17. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on conduct of pharmacovigilance for medicines used by the paediatric population: post-authorisation evaluation of medicines for human use. Jan 2007 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/ phvwp/23591005en.pdf[Accessed 2008 Dec 17]
18. European Medicines Agency. Revised priority list for studies into off-patent paediatric medicinal products: pre-authorisation evaluation of medicines for human use. Aug 2008 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/paediatrics/22698308en.pdf[Accessed 2008 Sep 29]
19. Child and Adolescent Psychiatry Trials Network [online]. Available from URL: http://www.captn.org [Accessed 2008 Jan 22]
20. Electronic medicines compendium. Zyprexa 2.5 mg, 5 mg, 7.5 mg, 10mg, 15 mg, and 20 mg coated tablets. Zyprexa Velotab 5mg, 10 mg, 15mg, and 20mg orodispersible tablets [online]. Available from URL: http://emc.medicines.org. uk/emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=614 [Accessed 2008 Feb 6]
21. Brown TM. Clozapine, neuroleptic malignant syndrome, and pancerebellar syndrome. Psychosomatics 1999; 40 (6): 518-20
22. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv 1998; 49 (9): 1163-72
23. Levenson J. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142 (10): 1137-45
24. Gracious BL, Findling RL. Antipsychotic medications for children and adolescents. Pediatr Ann 2001; 30 (3): 138-45
25. Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 2007; 46 (6): 267-700
26. Stigler KA, Potenza MN, Posey DJ, et al. Weight gain associated with atypical antipsychotic use in children and adolescents. Pediatr Drugs 2004; 6 (1): 33-44
27. Burns MJ. The pharmacology and toxicology of atypical antipsychotic agents. Clin Toxicol 2001; 39 (1): 1-14